Ilya Pharma presents clinical update at 9th Microbiome Movement Drug Development Summit, Boston 10-12 July
The work is funded by Ilya Pharma AB, Bio-X grant from STUNS in Uppsala and the Knut and Alice Wallenberg Foundation.
The company is insourcing business administration.
CXCL12-expressing Limosilactobacillus reuteri has clinically relevant antimicrobial effects of multidrug-resistant bacteria isolated from wounds of war victims in Ukraine Presented by Dr Andreas Fasth Poster ID 939